Mainstay Medical launches limited commercial launch of the neurostimulation system in the United States

ADD SUBJECT TO EMAIL ALERTS

Receive an email when new articles are published on

Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If this problem persists, please contact [email protected]

Back to Healio

Dublin-based Mainstay Medical has announced the launch of its ReActiv8 product in limited commercial quantities in the United States, according to a press release.

ReActiv8 is a neurostimulation implant system that treats persistent chronic low back pain in patients who have not gotten better with physical therapy or pain medication and are not candidates for spinal surgery, according to the press release. It will only be available to US patients through system-certified doctors from summer 2021.

“We’re starting on a limited scale to ensure we provide doctors with adequate training and help them select the right patients,” said Jason Hannon, CEO of Mainstay Medical, in the press release. “We look forward to expanding ReActiv8 availability in the US in the coming months, building on the momentum we have gained in Europe and Australia to further improve patient quality of life.”

In conjunction with the limited commercial launch, Mainstay Medical has launched a new website to educate physicians and patients about ReActiv8, as well as to provide tools, training, and guidance on the system.

“We expect these resources to help identify strong candidates for ReActiv8 and lead to compelling patient outcomes,” said Hannon.

ADD SUBJECT TO EMAIL ALERTS

Receive an email when new articles are published on

Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If this problem persists, please contact [email protected]

Back to Healio